Multilevel models improve precision and speed of IC50 estimates

Pharmacogenomics

Volumn 17, Issue 7, 2016, Pages 691-700

  Vis, Daniel J ^a,b   Bombardelli, Lorenzo ^b   Lightfoot, Howard ^c   Iorio, Francesco ^d   Garnett, Mathew J ^c   Wessels, Lodewyk F A ^a,b,e  

^a Center for Personalized Cancer Treatment   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^d EUROPEAN BIOINFORMATICS INSTITUTE   (United Kingdom)

^e DELFT UNIVERSITY OF TECHNOLOGY   (Netherlands)

Author keywords

dose response; IC50; mixed effects; nonlinear

Indexed keywords

1 [4 [(5 CYCLOPROPYL 1H PYRAZOL 3 YL)AMINO]PYRROLO[2,1 F][1,2,4]TRIAZIN 2 YL] N (6 FLUORO 3 PYRIDINYL) 2 METHYL 2 PYRROLIDINECARBOXAMIDE; 1 [5 CARBAMOYL 6 (2,4 DIFLUOROPHENYL) 2 PYRIDINYL] 1 (2,6 DIFLUOROPHENYL)UREA; 2 AMINO N [4 [5 (2 PHENANTHRENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]PHENYL]ACETAMIDE; ANTINEOPLASTIC AGENT; AZD 8055; CISPLATIN; DACINOSTAT; DACTOLISIB; DASATINIB; ELESCLOMOL; GSK 1904529A; JW 7 52 1; LUMINESPIB; MITOMYCIN; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; NSC 87877; PONATINIB; RAPAMYCIN; SHIKONIN; TANESPIMYCIN; TEMSIROLIMUS; UNCLASSIFIED DRUG; VISMODEGIB;

ARTICLE; BAYES THEOREM; CELL VIABILITY; DOSE RESPONSE; DRUG SENSITIVITY; DRUG TARGETING; IC50; LUNG CANCER CELL LINE; MATHEMATICAL MODEL; MEASUREMENT ACCURACY; MEASUREMENT ERROR; MULTILEVEL ANALYSIS; NONHUMAN; ALGORITHM; BIOLOGICAL MODEL; DRUG RESISTANCE; DRUG SCREENING; HUMAN; NONLINEAR SYSTEM; PERSONALIZED MEDICINE; PHARMACOGENETIC TESTING; PROCEDURES; STATISTICS AND NUMERICAL DATA; TUMOR CELL LINE;

ALGORITHMS; BAYES THEOREM; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; PHARMACOGENOMIC TESTING; PRECISION MEDICINE;

EID: 84973534378     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.16.15     Document Type: Article

References (10)

1. van der Greef J, Hankemeier T, McBurney RN. Metabolomics-based systems biology and personalized medicine: moving towards n = 1 clinical trials Pharmacogenomics 7(7), 1087-1094 (2006).
2. Vis DJ, Westerhuis JA, Jacobs DM et al. Analyzing metabolomics-based challenge tests. Metabolomics 11, 50-63 (2015).
3. Garnett MJ, Edelman EJ, Heidorn SJ et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483(7391), 570-575 (2012).
4. Barretina J, Caponigro G, Stransky N et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483(7391), 603-607 (2012).
5. Wellcome Trust Sanger Institute, Genomics of Drug Sensitivity in Cancer Website. www.cancerRxgene.org
6. Yang W, Soares J, Greninger P et al. Genomics of Drug Sensitivity in Cancer (GDSC): A resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 41(Database issue), D955-D961 (2013).
7. Calbo J, van Montfort E, Proost N et al. A functional role for tumor cell heterogeneity in a mouse model of small cell lung cancer. Cancer Cell 19(2), 244-256 (2011).
8. Lindstrom ML, Bates DM. Nonlinear mixed effects models for repeated measures data. Biometrics 46(3), 673-687 (1990).
9. R Core Team. A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria (2016). www.R-project.org/
10. Fallahi-Sichani M, Honarnejad S, Heiser LM, Gray JW, Sorger PK. Metrics other than potency reveal systematic variation in responses to cancer drugs. Nat. Chem. Biol. 9(11), 708-714 (2013).